Unidrug Innovative Pharma IPO Dates, Bid, Size, Allotment, Subscription, GMP, Listing, Price
Last Updated Date: Aug 31, 2023Let’s have a detailed review of the company and analytics of the Unidrug Pharma IPO release date, IPO offer price, subscription, Unidrug IPO allotment, grey market price and other details like the company’s background, Unidrug financial positions, its promoters, and other related things. 
Unidrug Innovative Pharma IPO Review & Ratings
| IPO Ratings & Review | |
| Criteria | Ratings |
| Industry Sentiments | 7.5/10 |
| Industry Ranking | 7.1/10 |
| Company Background | 7.3/10 |
| Company Reputation | 7.2/10 |
| Competitive Edge | 7.7/10 |
| Financial Statements | 7.1/10 |
| Popularity Index | 7.4/10 |
| Promoters Reputation | 7.7/10 |
| Retail Appetite | 7.1/10 |
| Top Brokers Review | 7.9/10 |
| Overall Ratings | 7.4/10 |
| Star Ratings | ★★★★☆ |
Summary of Unidrug Innovative Pharma IPO
They are presently engaged in the manufacturing of APIs and API intermediates for the domestic market as well as for exports to international markets.
Presently their product portfolio comprises of 11 APIs and API Intermediates such as Allopurinol, Alprazolam, Disulfiram, Etamsylate, Mefenamic Acid, Nitazoxanide, Propranolol HCL, Tinidazole, Baclofen, Guaifenesin and Ornidazole.
They develop and manufacture APIs for various therapeutic segments such as Antiprotozoal, Anti-Acute Gout, Anxiolytic, Alcohol Deterrent, Anti-Haemorrhagic, Non-Steroidal, Anti-Inflammatory, Antihypertensive, Anti-Spasmodic, Expectorant; Muscle Relaxant Ant-helmintic and Anti-Infective, etc for the Indian Pharmaceutical Market.
Currently, they are one of the leading manufacturers of Tinidazole and Ornidazole which are considered as antiprotozoal molecules, a segment of the bulk drug in Indian Pharmaceutical Markets.
The Promoters of this company are Jainesh Jain and Kanaklata Jain. The lead manager to the issue is Pantomath Capital Advisors Private Limited and the Registrar to this issue is Bigshare Services Private Limited.
Open Free* Demat A/C Now! Fill the details below
Unidrug Innovative Pharma IPO Date
The opening and the closing date of Unidrug Innovative Pharma IPO is not known yet.
Unidrug Innovative Pharma IPO Subscription
| Day / Date | QIB | NII | RII | Total Subscription |
| 1st Day – | ||||
| 2nd Day – | ||||
| 3rd Day – | ||||
| 4th Day – | ||||
| 5th Day – | ||||
| Shares Offered or Net Issue |
The shares subscribed by the public will be updated herein on a daily basis, once the IPO is open for subscription.
Unidrug Innovative Pharma IPO Allotment Status
Here, you can find the Allotment Status of this IPO.
Unidrug Innovative Pharma IPO Price Band
The face value of each share is Rs 10, but the price band of the IPO is not yet disclosed.
Unidrug Innovative Pharma IPO Equity Share Offering
Initial Public Issue of Upto 41,34,000 Equity Shares of face value Rs. 10 each fully paid of their Company for cash at a price of Rs. [●] per Equity Share (the “Issue Price”) (including a premium of Rs. [●] per Equity Share) aggregating up to Rs. [●] Lakhs.
Unidrug Innovative Pharma Limited – Company Overview
The Company was originally incorporated as “Uni Drug Private Limited” at Indore, as a Private Limited Company under the provisions of Companies Act, 1956 vide Certificate of Incorporation dated March 13, 1987 bearing Registration Number 3875, issued by the Registrar of Companies, Gwalior, Madhya Pradesh.
They are presently engaged in the manufacturing of APIs and API intermediates for the domestic market as well as for exports to international markets. APIs (Active Pharmaceutical Ingredients), also known as bulk drugs or bulk actives are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.
Presently their Product portfolio comprises of 11 APIs and API Intermediates such as Allopurinol, Alprazolam, Disulfiram, Etamsylate, Mefenamic Acid, Nitazoxanide, Propranolol HCL, Tinidazole, Baclofen, Guaifenesin and Ornidazole.
They develop and manufacture APIs for various therapeutic segments such as Antiprotozoal, Anti-Acute Gout, Anxiolytic, Alcohol Deterrent, Anti-Haemorrhagic, Non-Steroidal, Anti-Inflammatory, Antihypertensive, Anti-Spasmodic, Expectorant; Muscle Relaxant Ant-helmintic and Anti-Infective etc for the Indian Pharmaceutical Market.
The manufacturing facility has fully equipped quality control department with experienced and qualified staff to facilitate smooth manufacturing process. They have in-house testing laboratory and necessary infrastructure to test their raw materials and finished products to match the quality standards and as specified by the relevant pharmacopeia/ customers. The Company has marked its presence in both domestic as well as global markets.
They supply their product across all major states in the Country. Also, they export their products to countries such as China, Egypt, Chile, El Salvador, Honduras, Hong Kong, Peru, Santo Domingo, Singapore, Switzerland, Syria,Thailand, Ukraine, Vietnam etc.
Business strategies of Unidrug Innovative Pharma
- Expansion of Manufacturing Facility
- Increase their Global Presence through Exports
- To expand their API Products Portfolio
- Improving functional efficiency
Unidrug Innovative Pharma – Financial Statements
A quick look into the past financial performance of the company to understand its performance of business and evaluate the growth prospectus:
Financial Summary of Unidrug Innovative Pharma IPO
On the basis of Standalone statement:-
| Amount (in INR & lakhs) | |||
| 31-Dec-19 | 31-Mar-18 | 31-Mar-17 | |
| Total Assets | 1920.35 | 1777.89 | 1506.44 |
| Total Revenue | 3102.25 | 3257.52 | 2650.32 |
| Total Expense | 2652.12 | 3030.94 | 2616.33 |
| Profit After Tax | 322.09 | 149.23 | 23.47 |
Earnings per Equity Share (in lakhs)
| 31-Dec-19 | 31-Mar-18 | 31-Mar-17 | |
| Basic & Diluted | 4.20 | 1.95 | 0.31 |
From the above statements, one could find that Unidrug Innovative Pharma may perform well.
Unidrug Innovative Pharma IPO – Promoters
The Promoter of this company is:
- Jainesh Jain and
- Kanaklata Jain
List of Related Parties (Key Managerial Personnel)
- Mahesh Nabar, Chief Financial Officer
- Anamika Runwal, Company Secretary & Compliance Officer
Interest in Intellectual Rights of the Company
As on the date of filing of the Draft Red Herring Prospectus, the Company does not own any intellectual property rights.
Unidrug Innovative Pharma IPO Offer Details or Issue Details
| Particulars | No. Of Equity Shares |
| Issue of Equity Shares by The Company | Issue of up to 41,34,000* Equity Shares of face value of Rs. 10/- each fully paid up of the Company for cash at a price of Rs. [●]/- per Equity share aggregating Rs. [●] Lakhs |
| Consisting of: | |
| Market Maker Reservation Portion | [●] Equity Shares of face value of Rs. 10/- each fully paid up of the Company for cash at a price of Rs. [●] /- per Equity share aggregating Rs. [●] Lakhs. |
| Net Issue to the Public | Up to [●] Equity Shares of face value of Rs. 10/- each fully paid of the Company for cash at a price of Rs. [●] /- per share aggregating Rs. [●] Lakhs. |
| Of Which | |
| A. QIB Portion | No shares shall be reserved for allocation to QIBs |
| B. Retail Portion | [●] Equity Shares of face value of Rs. 10/- each. |
| C. Non-Institutional Portion | [●] Equity Shares of face value of Rs. 10/- each. |
| Pre and Post Issue Equity Shares | |
| Equity Shares outstanding prior to the Issue |
76,67,400 Equity Shares of face value of Rs.10/- each. |
| Equity Shares outstanding after the Issue |
Upto [●] Equity Shares of face value of Rs.10/- each. |
Unidrug Innovative Pharma IPO Issue Object
These are the IPO Issue Objects of the company
- To finance the expansion of their existing Manufacturing Unit;
- General corporate purposes.
Unidrug Innovative Pharma IPO – Basis of the Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Experienced Management Team;
- Multipurpose Manufacturing Plant;
- Quality Control and Quality Assurance:
- Scalable Business Model.
The relevant quantitative factors are:
On the basis of standalone statement:-
| Basic & Diluted EPS | RONW | NAV (Rs.) | |
| 31-Mar-19 | 4.20 | 32.24% | 13.03 |
| 31-Mar-18 | 1.95 | 22.05% | – |
| 31-Mar-17 | 0.31 | 4.45% | – |
- Price to Earnings (P/E) ratio in relation to Price Band of Rs. [●] to Rs. [●] per Equity Share of
Rs. 10/- each fully paid up:
| Particulars | P/E ratio |
| Highest | 14.52 |
| Average | 8.17 |
| Lowest | 11.61 |
- Competitive Peers:
Companies EPS PE Ratio RONW (%) NAV(per share) Face Value (per
share)Unidrug Innovative Pharma Technologies Limited 4.20 [●] 32.24 13.03 10.00 Aarti Drugs
Limited37.42 12.15 16.83 219.90 10.00 Granules India
Limited6.37 14.52 11.37 55.98 1.00
Unidrug Innovative Pharma IPO Lead Managers
| Lead Managers |
| PANTOMATH CAPITAL ADVISORS PRIVATE LIMITED 406-408, Keshava Premises, Behind Family Court, Bandra Kurla Complex, Bandra East, Mumbai – 400 051, Maharashtra, India Tel: +91-22 6194 6700 Fax: +91-22 2659 8690 Website:www.pantomathgroup.com Email: ipo@pantomathgroup.com Investor Grievance Id: ipo@pantomathgroup.com Contact Person: Unmesh Zagade SEBI Registration No:INM000012110 |
Unidrug Innovative Pharma IPO Registrar to offer
| Registrar to the Offer |
| BIGSHARE SERVICES PRIVATE LIMITED 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis, Makwana Road, Marol, Andheri East Mumbai – 400 059, Maharashtra Tel: +91 22 62638200 Fax: +91 22 62638299 Website: www.bigshareonline.com Email: ipo@bigshareonline.com Investor Grievance Id: investor@bigshareonline.com Contact Person: Babu Raphael SEBI Registration Number: INR000001385 |
Unidrug Innovative Pharma IPO Other Details:
- Statutory Auditor – S.N. Gadiya & Co.
- Peer Review Auditor – S. N. Gadiya & Co.
- Bankers to the Company – Kotak Mahindra Bank Limited
- Legal Advisor to the Issue – Zastriya (Attorneys and Legal Consultants)
Unidrug Innovative Pharma IPO Grey Market Premium
The Unidrug Innovative Pharma IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X.
Open Free* Demat A/C Now! Fill the details below
Market Guide
Featured Topics